幸福魔方
Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站
一 |
美媒 NBA Memes 晒出凯里-欧文相关图片，聊起了他和斯蒂芬-库里之间的经典对位较量。
该媒体给出看法：在整个联盟当中，欧文或许是为数不多，能够在任意一个比赛夜晚，与库里展开得分对轰的控球后卫，尤其是在压力拉满、关注度极高的关键大赛舞台上，这一特质会体现得更加明显。
二 |
欧文与库里生涯多次在重量级赛事直接交手，2016 年总决赛抢七便是两人对抗的名场面。
三 | 那场决战，欧文面对库里防守投进致胜三分，帮助骑士在 1‑3 落后的绝境下逆转勇士，拿下队史首座总冠军奖杯。 Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。
Current article:http://2arb1x.panningbuquanchencaibingzhang.cyou/news/20260826_5834578.html
Published on:00:00:00